ASTH

Based on Astrana Health, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Astrana Health do?

Astrana Health manages and coordinates medical care through a network of primary care physicians, specialists, and hospitalists across the United States. It uses a proprietary technology platform to deliver value-based care — focusing on patient outcomes rather than fee-for-service billing — and serves patients covered by Medicare, Medicaid, HMO plans, and private insurance.

Does ASTH pay dividends?

No, Astrana Health does not currently pay a dividend. The company is in an active growth phase, reinvesting capital into expanding its physician network and technology platform rather than returning cash to shareholders through distributions.

When does ASTH report earnings?

Astrana Health follows a standard quarterly earnings cadence for US-listed companies. For the most current reporting schedule and recent results, check the investor relations section of the company's official website.

Is ASTH a good stock to buy?

UQS Score rates ASTH as Below Average overall. The Growth pillar is a genuine strength, and Valuation reads as Good, but the Quality, Moat, and Risk pillars are all Weak — meaning investors take on meaningful uncertainty. Whether that trade-off fits your portfolio depends on your risk tolerance and time horizon. View the full pillar breakdown on UQS Pro.

Is ASTH overvalued?

The UQS Valuation pillar for ASTH is rated Good, suggesting the stock is not obviously overpriced relative to its fundamentals at current levels. However, valuation should always be considered alongside the company's Quality and Risk profile, both of which are Weak — meaning a lower price may reflect genuine business risk rather than a pure bargain.

How does ASTH compare to its competitors?

Astrana differentiates itself through its integrated physician-network model and proprietary population health technology, which sets it apart from facility-focused operators like Ardent Health and home-care specialists like Aveanna and Addus. However, its Weak Moat pillar suggests this differentiation has not yet translated into a durable competitive advantage by UQS criteria.

What is ASTH's market cap bracket?

Astrana Health is classified as a small-cap company. This means it carries higher liquidity risk and greater price volatility than large- or mega-cap healthcare peers, which is a factor investors should weigh alongside the company's Weak Risk pillar rating.

Who founded Astrana Health?

Astrana Health was incorporated in 1985 and has operated under various names, most recently changing from Apollo Medical Holdings to Astrana Health in February 2024. Detailed founding history and leadership background are available through the company's public filings and investor relations materials.

Is ASTH a long-term quality investment?

From a long-term quality perspective, ASTH's UQS profile presents a mixed picture. The Strong Growth pillar indicates the business is scaling, but Weak scores in Quality, Moat, and Risk suggest the foundation for sustained long-term compounding is not yet firmly established. Investors focused on quality durability may want to monitor how these pillars evolve over future reporting periods.

What is the main competitive advantage of Astrana Health?

Astrana's primary differentiator is its integrated value-based care model, combining a large physician network with a proprietary population health management platform. This positions it to capture shared savings from payers like Medicare Advantage plans. However, the UQS Moat pillar rates this advantage as Weak, indicating the edge is not yet considered deeply entrenched.

What sector does ASTH belong to?

Astrana Health operates in the Healthcare sector, specifically within physician management, care coordination, and value-based care services. It sits at the intersection of healthcare technology and managed care, serving patients, providers, and health plans across the United States.

Is ASTH a growth stock or value stock?

Based on UQS pillar labels, ASTH leans toward the growth category — its Growth pillar is rated Strong while Valuation is Good rather than deeply discounted. It is not a classic value play, but neither is it priced at a significant premium. The combination suggests a growth-oriented profile with moderate valuation risk.

Astrana Health, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

Astrana Health, Inc. is growing rapidly with strong revenue and earnings expansion.

Astrana Health, Inc. presents elevated risk with concerns around leverage or financial stability.

Astrana Health, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.

Astrana Health, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ASTH.

The UQS (Unified Quality Score) for Astrana Health, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Astrana Health, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Astrana Health, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.